Flux is building a next generation genetic medicine company based on groundbreaking science that integrates Targeted Ubiquitin Modulators (“TUMs”) with other innovations that overcome limitations of first-generation gene therapies. Their integrated technology platform will enable development of therapies for haploinsufficiency and other genetic disorders that cannot be addressed with current approaches.
